Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04595474 · ClinicalTrials.gov registry record

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes

A clinical trial of Type 1 Diabetes and Cirrhosis, Liver, sponsored by Joslin Diabetes Center.

Active
Registry status
533
Enrollment target
1
Study location

NCT04595474 is a study of Type 1 Diabetes and Cirrhosis, Liver that is active but no longer recruiting, run by Joslin Diabetes Center. The registered enrollment target is 533 participants, below the 821-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04595474, a study of Type 1 Diabetes and Cirrhosis, Liver, is active but no longer recruiting, sponsored by Joslin Diabetes Center.

ACTIVE NOT RECRUITING
Registry status
533 participants
Enrollment target
1
Study location

Study Summary

The aim of this study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes receiving care at Joslin clinic using noninvasive imaging and serum-based methods with the goal of identifying high-risk patients with advanced fibrosis who should be prioritized for specialty referral

Interventions

  • DEVICE Transient Elastography

Study Locations (1)

Massachusetts

  • Joslin Diabetes Center - Boston

Trial Details

FieldValue
Enrollment Target 533 participants
Start Date 2021-01-14
Est. Completion 2025-12-30

Sponsor

Joslin Diabetes Center

73 total trials

What the Registry Record Tells You About NCT04595474

The ClinicalTrials.gov registry entry for NCT04595474 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 533 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 821-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (35% lower). The listed sponsor is Joslin Diabetes Center, which has 73 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Transient Elastography is the first listed.

NCT04595474 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04595474 about?

NCT04595474 is a clinical study titled "Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes". The aim of this study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes receiving care at Joslin clinic using noninvasive imaging and serum-based methods with the goal of identifying high-risk patients with advanced fibrosis who should be priori...

What is the current status of trial NCT04595474?

This trial is currently active not recruiting. The enrollment target is 533 participants. The study started on 2021-01-14. Estimated completion is 2025-12-30.

What conditions does trial NCT04595474 study?

This clinical trial studies the following conditions: Type 1 Diabetes, Cirrhosis, Liver, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver, Fibrosis, Liver.

What interventions are being tested in trial NCT04595474?

The interventions under investigation include: Transient Elastography (DEVICE).

Who is sponsoring clinical trial NCT04595474?

This trial is sponsored by Joslin Diabetes Center, which has 73 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04595474 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.